Cibus, Inc.
Business
Cibus is an agricultural biotechnology company that develops plant traits using proprietary gene editing technologies, primarily its Rapid Trait Development System (RTDS), to create non-transgenic productivity traits for major crops. The company's business model centers on licensing developed traits to seed companies in exchange for royalties on seed sales, with near-term focus on herbicide-tolerance traits in rice targeting Latin America and the United States beginning in 2027. Cibus also operates a partially partner-funded sustainable ingredients program including biofragrance products using yeast genetics and fermentation.
Summary from 10-K filed 2026-03-17
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Total revenue | 4 | 4 | 2 | 157,000 | 26 | |
| Research and development | 44 | 50 | 42 | 12 | 11 | |
| Selling, general, and administrative | 27 | 31 | 29 | 11 | — | |
| Goodwill impairment | 21 | 181 | — | — | — | |
| Long-lived assets impairment | 9 | 0 | — | — | — | |
| Total operating expenses | 101 | 263 | 321 | 23 | 27 | |
| Loss from operations | −98 | −258 | −319 | −22 | −29 | |
| Royalty liability interest expense - related parties | −35 | −34 | −19 | 0 | — | |
| Other interest income, net | 438,000 | 631,000 | 527,000 | −87,000 | −1 | |
| Non-operating income, net | 400,000 | 9 | −395,000 | 6 | — | |
| Loss before income taxes | −132 | −283 | −338 | −17 | −29 | |
| Income tax expense | −29,000 | −29,000 | 4,000 | 0 | 0 | |
| Net loss | −132 | −283 | −338 | −17 | — | |
| Net loss attributable to noncontrolling interest and redeemable noncontrolling interest | −5 | −31 | — | — | — | |
| Net loss attributable to Cibus, Inc. stockholders | −127 | −251 | −268 | −17 | −29 | |
| Basic net loss per share of Class A common stock (in dollars per share) | −2.78 | −10.83 | −25.95 | −18.36 | −0.78 | |
| Diluted net loss per share of Class A common stock (in dollars per share) | −2.78 | −10.83 | −25.95 | −18.36 | −0.78 | |
| Weighted average shares of Class A common stock outstanding - basic (in shares) | 46 | 23 | 10 | 919,959 | 37 | |
| Weighted average shares of Class A common stock outstanding - diluted (in shares) | 46 | 23 | 10 | 919,959 | 37 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2023 2023-05-31 | FY 2022 2022-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 10 | 14 | 33 | — | 3 | |
| Accounts receivable | 503,000 | 1 | 500,000 | — | 0 | |
| Prepaid expenses and other current assets | 2 | 1 | 2 | — | 606,000 | |
| Total current assets | 12 | 17 | 35 | — | 4 | |
| Property, plant, and equipment, net | 6 | 11 | 16 | — | 5 | |
| Operating lease right-of-use assets | 22 | 33 | 22 | — | 14 | |
| Intangible assets, net | 32 | 34 | 35 | — | 0 | |
| Goodwill | 233 | 253 | 435 | 585 | 0 | |
| Other non-current assets | 926,000 | 1 | 1 | — | 0 | |
| Total assets | 305 | 350 | 544 | — | 22 | |
| Accounts payable | 8 | 6 | 6 | — | 340,000 | |
| Accrued expenses | 2 | 2 | 2 | — | 173,000 | |
| Accrued compensation | 3 | 3 | 4 | — | 107,000 | |
| Deferred revenue | 500,000 | 932,000 | 1 | — | 107,000 | |
| Current portion of notes payable | 435,000 | 436,000 | 833,000 | — | 0 | |
| Current portion of financing lease obligations | 0 | 113,000 | 187,000 | — | 97,000 | |
| Current portion of operating lease obligations | 3 | 4 | 6 | — | 367,000 | |
| Class A common stock warrants | 79,000 | 2 | 1 | — | 291,000 | |
| Other current liabilities | 0 | 288,000 | 16,000 | — | 479,000 | |
| Total current liabilities | 17 | 20 | 21 | — | 2 | |
| Notes payable, net of current portion | 93,000 | 226,000 | 536,000 | — | 0 | |
| Operating lease obligations, net of current portion | 30 | 31 | 17 | — | 13 | |
| Royalty liability - related parties | 235 | 199 | 165 | — | 0 | |
| Other non-current liabilities | 2 | 1 | 2 | — | 79,000 | |
| Total liabilities | 283 | 252 | 206 | — | 15 | |
| Commitments and contingencies (See Note 9) | — | — | — | — | — | |
| Redeemable noncontrolling interest | 0 | 6 | 45 | — | 0 | |
| Additional paid-in capital | 882 | 825 | 775 | — | 220 | |
| Class A common stock in treasury, at cost; 193,195 shares as of December 31, 2025, and 45,177 shares as of December 31, 2024 | −2 | −2 | −2 | — | −1 | |
| Accumulated deficit | −858 | −731 | −480 | — | −212 | |
| Accumulated other comprehensive income | 39,000 | 15,000 | 8,000 | — | 0 | |
| Total stockholders equity | 22 | 92 | 293 | — | 7 | |
| Total liabilities, redeemable noncontrolling interest, and stockholders equity | 305 | 350 | 544 | — | 22 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Depreciation and amortization | 6 | 7 | 5 | 2 | 2 | |
| Stock-based compensation | 8 | 11 | 16 | 4 | 2 | |
| Loss on disposal of assets, net | 41,000 | 335,000 | — | — | — | |
| Change in fair value of liability classified Class A common stock warrants | −447,000 | −9 | 1 | −5 | — | |
| Other | 38,000 | 22,000 | 21,000 | 0 | — | |
| Accounts receivable | 538,000 | −512,000 | 2 | 0 | 5 | |
| Prepaid expenses and other current assets | 983,000 | 518,000 | 1 | 389,000 | 3 | |
| Accounts payable | 720,000 | −188,000 | 2,000 | −229,000 | −360,000 | |
| Accrued expenses | −367,000 | 608,000 | −2 | −166,000 | — | |
| Accrued compensation | −268,000 | −535,000 | 891,000 | −2 | 572,000 | |
| Deferred revenue | −403,000 | −285,000 | −89,000 | −56,000 | — | |
| Right-of-use assets and lease obligations, net | 1 | 990,000 | −106,000 | 199,000 | — | |
| Other assets and liabilities, net | −28,000 | −213,000 | −431,000 | −610,000 | — | |
| Net cash used in operating activities | −51 | −58 | −46 | −19 | −19 | |
| Purchases of property, plant, and equipment | −578,000 | −808,000 | −4 | −2 | −497,000 | |
| Net cash used in investing activities | −578,000 | −808,000 | 55 | −2 | 11 | |
| Proceeds from issuances of securities | 50 | 44 | 20 | — | — | |
| Costs incurred related to issuances of securities | −2 | −2 | −2 | — | — | |
| Payment of taxes related to restricted stock units withheld from employees | −142,000 | −214,000 | −742,000 | 0 | 0 | |
| Proceeds from issuance of notes payable | 0 | 204,000 | 1 | 0 | — | |
| Repayments of financing lease obligations | −113,000 | −171,000 | — | — | — | |
| Repayments of notes payable | −995,000 | −912,000 | −1 | 0 | — | |
| Net cash provided by financing activities | 47 | 41 | 20 | 10 | 4 | |
| Effect of exchange rate changes on cash and cash equivalents | 11,000 | −13,000 | 3,000 | 0 | — | |
| Net decrease in cash and cash equivalents | −5 | −18 | 29 | −11 | −4 |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Cibus, Inc.'s CIK number?
Cibus, Inc.'s SEC CIK number is 0001705843 (1705843). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Cibus, Inc.'s SEC filings?
All of Cibus, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Cibus, Inc. last report earnings?
Cibus, Inc. (CBUS) most recently filed an earnings 8-K with the SEC on May 14, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001628280-26-035105). This is Cibus, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is Cibus, Inc.'s most recent earnings 8-K?
Cibus, Inc.'s latest earnings 8-K (Item 2.02) was filed May 14, 2026 under accession 0001628280-26-035105. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Cibus, Inc.'s latest earnings 8-K →
Look up any company's CIK number →